PMID- 26112844
OWN - NLM
STAT- MEDLINE
DCOM- 20160414
LR  - 20220317
IS  - 0971-5916 (Print)
IS  - 0975-9174 (Electronic)
IS  - 0971-5916 (Linking)
VI  - 141
IP  - 4
DP  - 2015 Apr
TI  - Effect of oral hypoglycaemic agents on bone metabolism in patients with type 2 
      diabetes mellitus & occurrence of osteoporosis.
PG  - 431-7
LID - 10.4103/0971-5916.159287 [doi]
AB  - BACKGROUND & OBJECTIVES: Type 2 diabetes mellitus (T2DM) is considered to be a 
      protective factor against development of osteoporosis. But oral hypoglycaemic 
      agents (OHA) are likely to increase the risk of osteoporosis. This study was 
      carried out to evaluate the effect of various OHA on bone mineral density (BMD) 
      in patients with T2DM. METHODS: Forty one patients (study group) with T2DM (mean 
      age 51.9+/-5.5 yr; 31 females) receiving treatment with oral hypoglycaemic agents 
      (OHA) [thiazolidinediones alone (n=14) or in combination with other OHA (n=27)] 
      for a period of at least three consecutive years and 41 age- and gender-matched 
      healthy controls (mean age 51.4+/-5.1 yr) were included in the study. A detailed 
      clinical history was taken and all were subjected to physical examination and 
      recording of anthropometric data. BMD was assessed for both patients and 
      controls. RESULTS: The mean body mass index (kg/m [2] ) (26.5+/-4.90 vs 27.3 +/-5.33) 
      and median [inter-quartile range (IQR)] duration of menopause (yr) among women 
      [6(2-12) vs 6(1-13)] were comparable between both groups. The bone mineral 
      density (BMD; g/cm [2] ) at the level of neck of femur (NOF) (0.761+/-0.112 vs 
      0.762+/-0.110), lumbar spine antero-posterior view (LSAP) (0.849+/-0.127 vs 
      0.854+/-0.135); median Z-score NOF 0.100[(-0.850)-(0.550)] vs 
      -0.200[(-0.800)-(0.600)], LSAP -1.200[(-1.700)-(-0.200)] vs -1.300 
      [(-1.85)-(-0.400)] were also similar in study and control groups. Presence of 
      normal BMD (9/41 vs 8/41), osteopenia (16/41 vs 18/41) and osteoporosis (16/41 vs 
      15/41) were comparable between the study and control groups. No significant 
      difference was observed in the BMD, T-scores and Z-scores at NOF and LSAP among 
      T2DM patients treated with thiazolidinediones; those treated with other OHA and 
      controls. INTERPRETATION & CONCLUSIONS: The present findings show that the use of 
      OHA for a period of three years or more does not significantly affect the BMD in 
      patients with T2DM.
FAU - Kumar, B Siddhartha
AU  - Kumar BS
AD  - Division of Rheumatology, Department of Medicine, Sri Venkateswara Institute of 
      Medical Sciences, Tirupati, India.
FAU - Ravisankar, A
AU  - Ravisankar A
FAU - Mohan, Alladi
AU  - Mohan A
FAU - Kumar, D Prabath
AU  - Kumar DP
FAU - Katyarmal, D T
AU  - Katyarmal DT
FAU - Sachan, Alok
AU  - Sachan A
FAU - Sarma, K V S
AU  - Sarma KV
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Med Res
JT  - The Indian journal of medical research
JID - 0374701
RN  - 0 (Hypoglycemic Agents)
SB  - IM
CIN - Indian J Med Res. 2015 Dec;142(6):768. PMID: 26831427
CIN - Indian J Med Res. 2015 Dec;142(6):769. PMID: 26831428
MH  - Absorptiometry, Photon
MH  - Adult
MH  - Bone Density/*drug effects
MH  - Bone Diseases, Metabolic/chemically induced/pathology
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/metabolism
MH  - Female
MH  - Femur Neck/drug effects
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Osteoporosis/chemically induced/metabolism/*physiopathology
PMC - PMC4510723
EDAT- 2015/06/27 06:00
MHDA- 2016/04/15 06:00
PMCR- 2015/04/01
CRDT- 2015/06/27 06:00
PHST- 2015/06/27 06:00 [entrez]
PHST- 2015/06/27 06:00 [pubmed]
PHST- 2016/04/15 06:00 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - IndianJMedRes_2015_141_4_431_159287 [pii]
AID - IJMR-141-431 [pii]
AID - 10.4103/0971-5916.159287 [doi]
PST - ppublish
SO  - Indian J Med Res. 2015 Apr;141(4):431-7. doi: 10.4103/0971-5916.159287.